Endoprosthesis

• US 20110160839A1
• Filed: 12/29/2009
• Published: 06/30/2011
• Est. Priority Date: 12/29/2009
• Status: Abandoned Application

• Current Assignee: Boston Scientific Scimed (Boston Scientific Corporation)
• Original Assignee: Boston Scientific Scimed (Boston Scientific Corporation)
• Inventors: Weber, Jan, Atanasoska, Liliana, Radhakrishnan, Rajesh
• Application Number:
  US12/649,007
• Publication Number:
  US 20110160839A1
• Time in Patent Office: Days
• US Class Current: 623/1.15
• CPC Class Codes: A61F 2/91 made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
• CPC Class Codes: A61F 2210/0004 bioabsorbable
• CPC Class Codes: A61F 2210/0076 multilayered, e.g. laminated structures
• CPC Class Codes: A61F 2230/0054 V-shaped
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body

Abstract

An endoprosthesis, e.g., a bioerodable stent, that is treated by plasma immersion ion implantation on the surface and optionally in the bulk. Releasable therapeutic agent, drug, or pharmaceutically active compound may be incorporated into the treated surface of the endoprosthesis to provide desired medical benefits.

Claims

17. An endoprosthesis comprising a member, the member further comprising a bioderodable, wherein at least a portion of the bulk of the member is treated by plasma immersion ion implantation.

18. The endoprosthesis of claim 17, wherein the portion treated by plasma immersion ion implantation is at least a portion of the bioerodable portion.

19. The endoprosthesis of claim 17, wherein the portion treated by plasma immersion ion implantation is disposed in the bulk of the member at a depth between 0 A and 2500 A.

20. The endoprosthesis of claim 17, wherein the portion treated by plasma immersion ion implantation includes a first portion adjacent a second untreated portion.

21. The endoprosthesis of claim 20, wherein the portion treated by plasma immersion ion implantation includes a first portion and a second portion, the first and second portions having different chemical compositions than the bulk material of the member.

22. The endoprosthesis of claim 21, wherein the first portion is at a first depth within the bulk of the member and the second portion is at a second depth within the bulk of the member.

23. The endoprosthesis of claim 21, wherein the first portion and the second portion at least partially overlap.

24. The endoprosthesis of claim 21 wherein the first portion and the second portion are at least partially concentric about the circumference of the member.

25. The endoprosthesis of claim 21, wherein the first portion and the second portion at least partially extend along the longitudinal axis of the endoprosthesis.

26. The endoprosthesis of claim 17 wherein the member is a connector of a stent.

27. The endoprosthesis of claim 17 wherein the member is a circumferential band of a stent.

28. The endoprosthesis of claim 17, wherein a plurality of portions of the bulk of the member are treated by plasma immersion ion implantation to different chemical compositions.

29. The endoprosthesis of claim 17, wherein the bioerodable material comprises a metal.

30. The endoprosthesis of claim 29, wherein the metal comprises iron, magnesium, or an alloy thereof.

31. The endoprosthesis of claim 17, wherein the bioerodable material comprises a polymer.

32. The endoprosthesis of claim 31, wherein the polymer comprises polydioxanone, polycaprolactone, polygluconate, polylactic acid-polyethylene oxide copolymer, modified cellulose, collagen, poly(hydroxybutyrate), polyanhydride, polyphosphoester, poly(amino acid), poly-L-lactide, poly-D-lactide, polyglycolide, poly(alpha-hydroxy acid), or combination thereof.

33. The endoprosthesis of claim 17, wherein the member comprises a non-bioerodable material.

34. The endoprosthesis of claim 33, wherein the non-bioerodable material comprises stainless steel, platinum enhanced stainless steel, cobalt-chromium alloy, nickel titanium alloy, or combination thereof.

35. An endoprosthesis comprising a member, the member further comprising:

a biodegradable portion, wherein at least a portion of a surface of the biodegradable portion is treated by plasma immersion ion implantation; and

wherein at least a portion of the bulk of the member is treated by plasma immersion ion implantation.

36. A method of forming an endoprosthesis comprising:

treating a portion of the surface of an endoprosthesis with plasma immersion ion implantation; and

treating a portion of the bulk material of a portion of the endoprosthesis with plasma immersion ion implantation.

1. An endoprosthesis comprising a member, the member further comprising a bioerodable portion, wherein at least a portion of a surface of the bioerodable portion is treated by plasma immersion ion implantation.

2. The endoprosthesis of claim 1, wherein the portion of the surface treated by plasma immersion ion implantation includes a region of enhanced surface-area morphology.

3. The endoprosthesis of claim 1, wherein the member is a connector of a stent

4. The endoprosthesis of claim 1, wherein the member is a circumferential band of a stent.

5. The endoprosthesis of claim 1, wherein the surface is an abluminal surface.

6. The endoprosthesis of claim 1, wherein the surface is a luminal surface.

7. The endoprosthesis of claim 1, wherein the surface is a sidewall surface.

8. The endoprosthesis of claim 1, wherein a coating is deposited over the treated surface.

9. The endoprosthesis of claim 8, wherein the coating comprises a tie layer, a biocompatible outer coating, a radiopaque metal or alloy, a drug-eluting layer, or a combination thereof.

10. The endoprosthesis of claim 1, wherein at least one releasable therapeutic agent, drug, or pharmaceutically active compound is incorporated into the treated surface.

11. The endoprosthesis of claim 10, wherein the releasable therapeutic agent, drug, or pharmaceutically active compound comprises anti-thrombogenic agent, antioxidant, anti-inflammatory agent, anesthetic agent, anti-coagulant, antibiotic, or combination thereof.

12. The endoprosthesis of claim 1 wherein the bioerodable material comprises a metal.

13. The endoprosthesis of claim 12, wherein the metal comprises iron, magnesium, or an alloy thereof.

14. The endoprosthesis of claim 1, wherein the bioerodable material comprises a polymer.

15. The endoprosthesis of claim 14, wherein the polymer comprises polydioxanone, polycaprolactone, polygluconate, polylactic acid-polyethylene oxide copolymer, modified cellulose, collagen, poly(hydroxybutyrate), polyanhydride, polyphosphoester, poly(amino acid), poly-L-lactide, poly-D-lactide, polyglycolide, poly(alpha-hydroxy acid), or combination thereof.

16. The endoprosthesis of claim 1, wherein the member comprises a non-bioerodable material.

37. The method of claim 36 wherein the portion of the surface treated comprises a bioerodable portion of the endoprosthesis.

38. The method of claim 36 wherein the portion of the surface treated comprises an enhanced surface-area morphology.

39. The method of claim 36 wherein the portion of the bulk material treated comprises a first treated portion having a different chemical composition than the bulk material.

40. The method of claim 36 wherein the portion of the bulk material treated is treated by plasma immersion ion implantation at a depth between 0 A and 2500 A.

38-1. The method of claim 36 wherein the portion of the bulk material treated comprises a bioerodable portion of the endoprosthesis.